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Summary
Quality of life is a measure not only of disease severity and its functional impact (physical, 
psychological, and social functioning) but also the efficacy of novel therapies. The aim of this 
study was to analyze the quality of life in cystic fibrosis patients depending on the severity of 
the disease and methods of its treatment.
The study included groups of cystic fibrosis patients: 1) after lung transplantation, 2) requiring 
chronic oxygen therapy, and 3) in stable clinical status. Forty-five men and women older than 
18 years were enrolled. The participants were examined with the Polish version of the Cystic 
Fibrosis Quality of Life Questionnaire (CFQoL) adapted by Dębska & Mazurek.
Patients from analyzed groups differed significantly in terms of their quality of life in most 
of the subscales included in CFQoL, but not in Future Concerns and Interpersonal Relationships.
Although lung transplantation markedly improves the quality of life of patients with cystic 
fibrosis, they still experience problems with social functioning and future concerns.
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IntroductIon
Quality of life is a measure not only of disease severity 
and its functional impact (physical, psychological, and 
social functioning) but also the efficacy of novel thera-
pies. The results of clinical observations suggest that 
lung transplantation is the only treatment modality 
which can improve the survival in patients with advan-
ced cystic fibrosis [7,9]. In view of longer survival, the 
issues of improved physical, social, and psycho-emotio-
nal functioning become of vital importance.
A total of 67 single lung transplantations and 602 bila-
teral transplantations were carried out in the Euro-
transplant member countries in 2012. The number 
of transplants was highest in Germany, Belgium, and 
Austria [18]. Every year, approximately 1,600 single or 
bilateral lung transplantations are carried out worl-
dwide. Overall, 1.3 thousand lung transplantations were 
performed in individuals under 18 years of age during 
the last 15 years, most often between 12 and 17 years of 
age [10,20].
Lung transplantation in cystic fibrosis patients has been 
performed successfully for more than 20 years. Accor-
ding to the data gathered by the International Society for 
Heart and Lung Transplantation (ISHLT), cystic fibrosis 
is the third most frequent cause of lung transplantation 
in adults, which is reflected by constant improvement of 
survival in patients with this condition [21].
Unfortunately, only a few transplantations are per-
formed every year in the majority of centers, which, 
in the experts’ opinion, is reflected by an increased 
risk of mortality within one year after the procedure 
[10,12,15,20,21]. However, this situation is changing on 
a yearly basis, as dynamic progress in transplantology 
and the resultant increase in experience of relevant spe-
cialists leads to a decrease in perioperative mortality [2].
However, aside from the higher number of transplan-
tations and decreased risk of perioperative morbidity, 
improved quality of life is also a prerequisite of thera-
peutic success in patients with cystic fibrosis, irrespec-
tive of their age, severity of the disease, and type of its 
treatment. Assessment of the quality of life in various 
functional areas and identification of potential dysfunc-
tion in role functioning will allow holistic individuali-
zed care to be offered to patients with cystic fibrosis. 
Only the situation in which a patient has a possibility 
of self-realization without the stigma of the disease and 
related risks can be considered complete therapeutic 
success.
The aim of this study was to analyze the quality of life in 
cystic fibrosis patients depending on the severity of the 
disease and methods of its treatment.
MaterIals and Methods
The study was conducted at the Department of Pneumo-
nology and Cystic Fibrosis of the Tuberculosis and Lung 
Diseases Institute in Rabka-Zdroj. Enrollment in the 
study was voluntary, and all the participants gave their 
written informed consent to participate in the project.
The study included patients with various stages of cystic 
fibrosis. Forty-five men and women older than 18 years 
were enrolled, and divided into three subgroups desi-
gnated as A, B, and C. Subgroup A included 10 patients 
after lung transplantation. The time elapsed after the 
transplantation ranged from three months to three 
years and one month; three patients underwent trans-
plantation within one year prior to the study. Subgroup 
B (n=15) comprised patients in poor clinical status, rece-
iving chronic oxygen therapy and qualified for lung 
transplantation. Subgroup C (n=20) included patients in 
stable clinical status. The lack of significant limitations 
in physical activity and no necessity of oxygen therapy 
constituted inclusion criteria for this subgroup.
We used the Polish version of the Cystic Fibrosis Quality 
of Life Questionnaire (CFQoL), developed by Gee et al. 
[8] and adapted by Dębska & Mazurek [6]. The question-
naire comprises 54 questions grouped in the subscales 
of Physical Functioning (PF), Social Functioning (SF), Treat-
ment Issues (TI), Chest Symptoms (CS), Emotional Functio-
ning (EF), Future Concerns (FC), Interpersonal Relationships 
(IR), Body Image (BI), and Career Concerns (CC).
The results of each subscale were transformed into 
numeric values ranging between 0 and 100 points (with 
100 points corresponding to the optimal quality of life). 
Answers to individual questions were expressed on a 
6-item scale, where 1 corresponded to the lowest, and 
6 to the highest score (except for question no. 6, which 
was scored in a reverse order). Raw scores of individual 
questions equal to or lower than 3 points and trans-
formed score ≤50 points corresponded to poor quality 
of life.
Author’s address:
Abbreviations:
Grażyna Dębska, Andrzej Frycz Modrzewski Cracow University, 30-705 Cracow, ul. Herlinga Gru-
dzińskiego 1; e-mail: gdebska@afm.edu.pl
BI – Body Image, CC – Career Concerns, CFQoL – Cystic Fibrosis Quality of Life Questionnaire, 
CS – Chest Symptoms, EF – Emotional Functioning, FC – Future Concerns, IR – Interpersonal 
Relationships, ISHLT – International Society for Heart and Lung Transplantation, PF – Physical 
Functioning, SF – Social Functioning, TI – Treatment Issues.
500
Postepy Hig Med Dosw (online), 2014; tom 68: 498-502
not require oxygen therapy (subgroup C) was variable. 
The global quality of life score amounted to x=70.8±15.7 
points. The highest average scores were documented in 
the case of Physical Functioning (x=84.2±15.46) and Social 
Functioning subscales (x=81.1±16.96). The average scores 
of the remaining subscales – Chest Symptoms, Emotional 
Functioning, Treatment Issues, Career Concerns, Interpersonal 
Relationships, and Body Image – ranged from x=76.61±5.7 
to x=63.2±23.5. The lowest average score, being at the 
threshold of low quality of life, was recorded in the case 
of the Future Concerns subscale (x=51.9±19.2; Table 1).
The average scores of most subscales in the group 
of patients awaiting the transplantation (subgroup 
B) ranged between 32±15.4 and 55.0±17.6 points, and 
were significantly lower than in individuals after the 
transplantation (subgroup A, from 50.0±20.1 to 95.5±10.1 
points) or those in stable clinical status (subgroup C, 
from 51.9±19.2 to 84.2±15.5 points). Only in the case of 
two subscales, Future Concerns and Interpersonal Rela-
tionships, did the intergroup differences prove insignif-
icant (p>0.05). Finally, the average quality of life score 
in the Treatment Issues subscale was significantly higher 
in patients from subgroup A than in the participants 
from subgroups C and B (95.5±10.12 vs. 43.7±19.04 vs. 
76.6±15.73 points, p<0.001; Table 2).
dIscussIon
our analysis of the quality of life in patients with various 
stages of cystic fibrosis unambiguously confirmed that 
patient’s status constitutes the determinant of functio-
ning in many areas. Our study confirmed good functio-
ning of patients after transplantation in physical, social, 
and emotional spheres. Our participants were not bothe-
red by questions related to treatment or the presence 
of respiratory symptoms. In contrast, they reported 
low quality of life regarding future concerns, work and 
education, and body image. In turn, the patients in the 
worst clinical status who were qualified for the trans-
plantation presented the lowest quality of life in all 
The characteristics of the quality of life in various func-
tional domains were presented as mean values and their 
standard deviations, medians, and interquartile ranges. 
Normal distribution of the analyzed parameters was 
verified with the Shapiro-Wilk test. The Kruskal-Wallis 
test and Dunn post-hoc test were used for comparison of 
the scores of three studied subgroups. Statistical signifi-
cance of the tests was set at p≤0.05. The statistical analy-
sis was conducted with Statistica 6.0 software (StatSoft, 
Tulsa, OK, United States).
results
the average transformed scores of most subscales 
in patients after lung transplantation (subgroup A) 
exceeded 50. The global quality of life score in this 
group amounted to x=73.9±7.9. Participants from group 
A reported the highest quality of life (the highest aver-
age scores) in Chest Symptoms (x=95±10.1), Treatment 
Issues (x=95.3±8.9), and Emotional Functioning subscales 
(x=87.3±12.8). Also the quality of life in Physical Function-
ing and Social Functioning subscales was high, amounting 
to x=82.4±26.1 and 73.0±18.4, respectively.
In contrast, the lowest quality of life scores were docu-
mented in the case of Career Concerns (50.0±21.1), Future 
Concerns (56.0±11.8), Body Image (69.3±17.8), and Interper-
sonal Relationships (Table 1).
Both the average transformed global quality of life score 
and the average transformed scores of most subscales 
determined in the subgroup of patients awaiting lung 
transplantation (subgroup B) were lower than 50 points, 
pointing to low quality of life in this group. The only excep-
tions pertained to Emotional Functioning and Future Concerns 
subscales, the average scores of which were 55.0±17.6 and 
50.0 ±20.6 points, respectively. The average global quality of 
life score equaled 42.6 ±12.42 points (Table 1).
The distribution of the average transformed quality of 
life scores in patients in stable clinical status who did 
Table 1. Statistical characteristics of the quality of life scores (means ± standard deviations) in patients after lung transplantation (subgroup A), awaiting lung 
transplantation (subgroup B), and at a stable stage of the disease (subgroup C)
Parameter Subgroup A (n=10) Subgroup B (n=15) Subgroup C (n=20)
Physical Functioning (PF) 90.6±8.5 34.1±22.0 84.2±15.5
Social Functioning (SF) 73.0±18.4 34.8±22.5 81.1±17.0
Treatment Issues (TI) 95.3±8.9 39.8±19.4 68.1±20.1
Chest Symptoms (CS) 95.5±10.1 43.7±19.0 76.6±15.7
Emotional Functioning (EF) 87.3±12.8 55.0±17.6 77.6±19.6
Future Concerns (FC) 56.0±11.8 50.0±20.6 51.9±19.2
Interpersonal Relationships (IR) 60.6±13.2 47.5±14.6 63.2±23.5
Body Image (BI) 69.3±17.8 41.7±23.8 64.6±23.2
Career Concerns (CC) 55.0±10.0 32.0±15.4 65.3±25.8
Global quality of life 73.9±7.9 42.6±12.4 70.8±15.7
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domains. Health and family were the highest values for 
this group of patients. Optimistic look into the future 
enables them to verify the purpose and sense of life, 
while gaining satisfaction from overcoming the disease 
and achieving previously defined objectives [5,13,14,19].
However, this does not exclude the risk of adverse 
effects, especially when the purpose and sense of life are 
lost, and in the presence of negative emotions (anxiety, 
depressive behavior, depression). They can generate 
suicidal behaviors, as revealed in the previous study by 
Cepuch et al. [4].
However, one cannot disagree with the opinions presen-
ted by Quinter et al. [16] and Singer et al. [17], according 
to whom the validation of existing tools and implemen-
tation of research findings during the care of patients 
constitute a chance for future studies, and thus also for 
therapeutic success in a wide sense. Identification of 
specific determinants of the quality of life at each stage 
of cystic fibrosis and its treatment, especially in longitu-
dinal studies, still seems an open area of research. Asses-
sment of the other functional domains of the patients, 
not necessarily from the perspective of the physical 
health domain, deserves particular attention.
The data published by Dębska et al. [5] suggest that com-
parison between the results of various studies is diffi-
cult if the quality of life was determined with different 
instruments; in this study we used the WHOQOL-BREF 
questionnaire, adapted by Wołowicka and Jaracz [22].
Our study confirmed the conclusion that the quality of 
life assessment is an important component of the the-
rapeutic process, especially when the treatment raises 
hopes for better life. Therefore, in this study we focu-
functional spheres. It should be noted, however, that 
undergoing transplantation does not release the patient 
from anxiety and life concerns. It cannot be excluded 
that the constant, negative emotional tension of the 
patient can become an additional factor modulating the 
duration of survival after transplantation.
Other authors pointed to health-related quality of life as 
a prognostic factor of survival [1,21]. Havermans et al. 
[11] identified anxiety and depression as the sources of 
worse social and emotional functioning and disturbed 
body image.
Noticeably, our study revealed that both the patients in 
stable clinical status and those subjected to transplanta-
tion experienced problems with body image and inter-
personal relationships. It cannot be excluded that the 
disease, namely cystic fibrosis, stigmatizes a patient in 
his/her own opinion. Lack of acceptance of body image, 
and self-imposition of barriers in social relationships 
can markedly hinder establishment of partner relation-
ships, and generate negative emotional states. Accor-
ding to Besier et al. [3], patients with cystic fibrosis 
who stay in partner relationships show greater satisfac-
tion with life and health than those who lack a partner. 
Satisfaction with family, sexual, and professional life in 
the group of patients with cystic fibrosis can positively 
affect the therapeutic outcome, irrespective of the tre-
atment method. Unfortunately, the number of reports 
dealing with the problem in question is sparse.
Moreover, the results of other studies suggest that 
patients with cystic fibrosis are satisfied with the quality 
of their life and health after lung transplantation. They 
show the best functioning in the physical sphere, but 
some deficits exist in the social and environmental 
Table 2. Comparison of the quality of life scores (medians, interquartile ranges) in patients after lung transplantation (subgroup A), awaiting lung transplantation 
(subgroup B), and at a stable stage of the disease (subgroup C)
Parameter Subgroup A (n=10) Subgroup B (n=15) Subgroup C (n=20) p-value
Physical Functioning (PF) 91 (82.4-100) 28 (22-54) 88 (76-94) <0.0011
Social Functioning (SF) 77.5 (60-85) 32.4 (15-50) 85 (70-95) <0.0012
Treatment Issues (TI) 100 (93.3-100) 37.3 (20-60) 66.7 (60-80) <0.0013
Chest Symptoms (CS) 100 (100-100) 45 (30-55) 80 (65-85) <0.0014
Emotional Functioning (EF) 91.3 (75-100) 52.5 (40-70) 77.5 (62.5-97.5) 0.0015
Future Concerns (FC) 55 (46.7-66.7) 40 (36.7-66.7) 50 (36.7-70) 0.469
Interpersonal Relationships (IR) 65 (52-70) 44 (36-58) 66 (44-78) 0.057
Body Image (BI) 66.7 (53.5-93.3) 40 (20-53.3) 66.7 (40-80) 0.0086
Career Concerns (CC) 55 (50-65) 30 (20-50) 70 (40-85) 0.0017
Global quality of life 74.2 (67.3-80.8) 38.8 (35.4-48.8) 73.1 (52.3-80.4) <0.0018
1Group A vs. B: p<0.001, Group A vs. C: p>0.999, Group B vs. C: p<0.001; 2Group A vs. B: p=0.009, Group A vs. C: p>0.999, Group B vs. C: p<0.001; 
3Group A vs. B: p<0.001, Group A vs. C: p=0.020, Group B vs. C: p=0.012; 4Group A vs. B: p<0.001, Group A vs. C: p=0.066, Group B vs. C: p=0.002; 
5Group A vs. B: p=0.001, Group A vs. C: p=0.638, Group B vs. C: p=0.012; 6Group A vs. B: p=0.023, Group A vs. C: p>0.999, Group B vs. C: p=0.023; 
7Group A vs. B: p=0.024, Group A vs. C: p>0.999, Group B vs. C: p<0.001; 8Group A vs. B: p<0.001, Group A vs. C: p>0.999, Group B vs. C: p<0.001
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life with regards to physical and social functioning, but 
experience problems with body image, interpersonal 
relationships, and future concerns, including work and 
education. Individuals qualified for the transplantation 
presented the lowest scores in all domains of quality of 
life.
sed on the quality of life assessment in a small group of 
patients with cystic fibrosis who had an opportunity to 
undergo lung transplantation.
In conclusion, our study revealed that patients after 
lung transplantation positively assess their quality of 
references
[1] Abbott J., Hart A., Morton A.M., Dey P., Conway S.P., Webb A.K.: 
Can health-related quality of life predict survival in adults with cys-
tic fibrosis? Am. J. Respir. Crit. Care Med., 2009; 179: 54-58
[2] Aratari M.T., Venuta F., De Giacomo T., Rendina E.A., Anile M., 
Diso D., Francioni F., Quattrucci S., Rolla M., Pugliese F., Liparulo V., 
Di Stasio M., Ricella C., Tsagkaropoulos S., Ferretti G., Coloni G.F.: 
Lung transplantation for cystic fibrosis: ten years of experience. 
Transplant. Proc., 2008; 40: 2001-2002
[3] Besier T., Schmitz T.G., Goldbeck L.: Life satisfaction of adolescents 
and adults with cystic fibrosis: impact of partnership and gender. J. 
Cyst. Fibros., 2009; 8: 104-109
[4] Cepuch G., Dębska G., Pawlik L., Mazurek H.: Patient’s perception 
of the meaning of life in cystic fibrosis - its evaluation with respect 
to the stage of the disease and treatment. Postępy Hig. Med. Dośw., 
2012; 66: 714-721
[5] Dębska G., Cepuch G., Pawlik L.: Postrzeganie życia jego celu i 
sensu przez chorych na mukowiscydozę po przeszczepie płuc. Folia 
Med. Cracov., 2011; 51: 19-28
[6] Dębska G., Mazurek H.: Walidacja polskiej wersji kwestionariusza 
CFQoL u chorych na mukowiscydozę. Pol. Merkur. Lekarski, 2007; 
23: 340-343
[7] Diso D., Anile M., Patella M., Pecoraro Y., Rendina E.A., Carillo C., Rus-
so E., Onorati I., Angioletti D., Ruberto F., Mazzesi G., Marullo A.G., Frati 
G., Venuta F.: Lung transplantation for cystic fibrosis: outcome of 101 
single-center consecutive patients. Transplant. Proc., 2013; 45: 346-348
[8] Gee L., Abbott J., Conway S.P., Etherington C., Webb A.K.: Develop-
ment of a disease specific health related quality of life measure for 
adults and adolescents with cystic fibrosis. Thorax, 2000; 55: 946-954
[9] Gomez C., Reynaud-Gaubert M.: Long-term outcome of lung 
transplantation. Rev. Pneumol. Clin., 2010; 67: 64-73
[10] Grodzki T.: Dylematy transplantologii płuc w Polsce. Pneumonol. 
Alergol. Pol., 2007; 75: 251-255
[11] Havermans T., Colpaert K., Dupont L.J.: Quality of life in patients 
with cystic fibrosis: association with anxiety and depression. J. Cyst. 
Fibros., 2008; 7: 581-584
[12] Jastrzębski D.: Komentarz do pracy Tomasza Grodzkiego: Dy-
lematy transplantologii płuc w Polsce. Pneumonol. Alergol. Pol., 
2008; 76: 68-69
[13] Lu B.R., Esquivel C.O.: A review of abdominal organ transplanta-
tion in cystic fibrosis. Pediatr. Transplant., 2010; 14: 954-960
[14] Oshrine K., McGrath D., Goldfarb S.: Transplanting the ado-
lescent cystic fibrosis patient: can we do it? Ther. Adv. Respir. Dis., 
2013; 7: 101-109
[15] Paduszyński G.: Przeszczepy płuc – tego sukcesu nikt nam nie 
odbierze! Mukowiscydoza, 2011; 28: 35-39
[16] Quinter A.L., Barker D.H., Blackwell L.S., Romero S.L., Woo M.S.: 
The importance of measuring health-related quality of life. Proc. 
Am. Thorac. Soc., 2009; 6: 624-625
[17] Singer J.P., Chen J., Blanc P.D., Leard L.E., Kukreja J., Chen H.: A 
thematic analysis of quality of life in lung transplant: the existing 
evidence and implications for future directions. Am. J. Transplant., 
2013; 13: 839-850
[18] Statistics per year in Eurotransplant 2012 http://www.eu-
rotransplant.org/cms/index.php?page=yearlystats (09.05.2013)
[19] Taylor J.L., Smith P.J., Babyak M.A., Barbour K.A., Hoffman B.M., 
Sebring D.L., Davis R.D., Palmer S.M., Keefe F.J., Carney R.M., Csik I., 
Freedland K.E., Blumenthal J.A.: Coping and quality of life in patients 
awaiting lung transplantation. J. Psychosom. Res., 2008; 65: 71-79
[20] W Zabrzu będzie więcej przeszczepów płuc u chorych z mu-
kowiscydozą. http://naukawpolsce.pap.pl/aktualnosci/news,39-
0877,w-zabrzu-bedzie-wiecej-przeszczepow-pluc-u-chorych-z-
mukowiscydoza.html (9.05.2013)
[21] Wojarski J., Pogorzelski A., Mazurek H.: Przeszczepienie płuc. In: 
Mukowiscydoza. Medical Tribune, Warszawa 2012, 19-139
[22] Wołowicka L., Jaracz K.: Polska wersja WHOQOL-100 i WHOQOL-
-BREF. In: Jakość życia w naukach medycznych, ed. J. Wołowicka. 
Poznań 2001
The authors have no potential conflicts of interest to declare.
